AstraZeneca PLC - Cambridge, England-based pharmaceutical firm - Reports that the US Food & Drug Administration withdrew its authorisation for the emergency use of Evusheld, a medicine used to prevent Covid-19 in adults and adolescents, for the emergency use for pre-exposure prophylaxis of Covid-19 in the US. Says that the FDA will make a determination about reinstating authorisation of Evusheld if the national prevalence of resistant variants decreases to 90%. Explains that the withdrawal is due the sustained high frequency of circulating SARS-CoV-2 variants that Evusheld does not retain in vitro neutralisation against.
Current stock price: 10,809.75 pence
12-month change: up 22%
By Abby Amoakuh, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2023 Alliance News Limited. All Rights Reserved.
Astrazeneca (AZN)
